Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 14
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | ||
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | ||
| NCT04214860 | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | ||
| NCT03931291 | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | ||
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | ||
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | ||
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | ||
| NCT06260514 | Study of APR-1051 in Patients With Advanced Solid Tumors | ||
| NCT00900614 | Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer | ||
| NCT04905914 | Study of ATRN-119 in Patients with Advanced Solid Tumors | ||
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | ||
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | ||
| NCT03588078 | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | ||
| NCT04638309 | APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) |
